Mutations in these genes therefore (in addition to PIK3CA and PTEN) warrant evaluation as potential determinants of sensitivity to mTOR inhibitors currently in clinical trials for HNSCC [49]. This evidence concerns the gene PTEN and head and neck squamous cell carcinoma.